Levocarnitine Pregnancy Warnings
Use is not recommended unless clearly needed.
US FDA pregnancy category: B
Comments:
-Stopping treatment in a pregnant woman with primary systemic carnitine deficiency may carry serious consequences; the risk of stopping treatment may outweigh the theoretical risks to the fetus of continuing.
Animal studies showed no evidence of impaired fertility or fetal harm, however at 600 mg/kg daily there was a statistically insignificant increase in post implantation losses. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
See references
Levocarnitine Breastfeeding Warnings
Benefit should outweigh risk.
Excreted into human milk: Data not available
Excreted into animal milk: Yes
Comments:
-Levocarnitine is a normal component of human milk.
-Levocarnitine concentration in milk is increased in dairy cows after exogenous administration.
-The risks to the infant from excess carnitine intake should be weighed against the benefits of supplementation to the mother.
See references
